Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06274385 · ClinicalTrials.gov registry record · NA
The Effects of an Acute Dose of a Betalain-rich Concentrate on Repeated-sprint Cycling Performance and Recovery.
A NA study of Nutraceuticals, sponsored by Drexel University.
- Recruiting
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT06274385: Recruiting NA study of Nutraceuticals, sponsored by Drexel University.
NCT06274385 is a NA study of Nutraceuticals that is actively recruiting participants, run by Drexel University. The registered enrollment target is 10 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06274385, a NA study of Nutraceuticals, is actively recruiting participants, sponsored by Drexel University.
- RECRUITING
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
Betalains have well-known antioxidant and anti-inflammatory properties. Recent investigations examining the effects of a betalain-rich concentrate (BRC) on exercise and recovery performance show promise of BRC as an ergogenic aid. To date, no study has examined the effects of a single dose of a BRC on supramaximal performance and recovery. Therefore, the purpose of this study is to examine the effects of an acute dose of BRC on repeated-sprint cycling performance and recovery.
Primary Outcome
Absolute and relative measures of peak, average, and minimum power (Watts). Also, the time to peak power and average power during the first and second half of each 30 s sprint.
Conditions Studied
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT Betalain-rich concentrate (AltRed)
Study Locations (1)
Pennsylvania
- Drexel University - Health Sciences Building - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2024-03-06 |
| Est. Completion | 2025-08 |
| Phase | NA |
What NCT06274385 shows while recruiting
NCT06274385 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Nutraceuticals appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06274385 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06274385 about?
NCT06274385 is a clinical study titled "The Effects of an Acute Dose of a Betalain-rich Concentrate on Repeated-sprint Cycling Performance and Recovery.". Betalains have well-known antioxidant and anti-inflammatory properties. Recent investigations examining the effects of a betalain-rich concentrate (BRC) on exercise and recovery performance show promise of BRC as an ergogenic aid. To date, no study has examined the effects of a single dose of a BRC ...
What is the current status of trial NCT06274385?
This trial is currently recruiting. It is a NA study. The enrollment target is 10 participants. The study started on 2024-03-06. Estimated completion is 2025-08.
What conditions does trial NCT06274385 study?
This clinical trial studies the following conditions: Nutraceuticals.
What interventions are being tested in trial NCT06274385?
The interventions under investigation include: Placebo (OTHER), Betalain-rich concentrate (AltRed) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06274385?
This trial is sponsored by Drexel University, which has 92 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06274385 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06274385's enrollment target sits among peer trials
10 1927th of 2000 higher than 26 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI